Stem Cell Innovations ( has begun to validate a set of compounds that Circomed ( develops for certain cardiovascular indications.

“We selected the C3A cell-line as it allows us to rapidly study human liver processes in a reproducible manner,” explains Barbara Staehelin, CEO of Circomed.
“This agreement confirms the broad applicability of our proprietary human liver cell C3A,” states Stem Cell Innovations’ CEO, James Kelly. “Initially developed to serve in a liver assist device, the C3A cell has become the firm fundament under our in vitro technology suite to study compound effects for both safety and efficacy.”

Next articleUMMZ Periodical Cicada Page